Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer biopsy study: fewer needle passes may be enough for genetic tests

NCT ID NCT05560776

Knowledge-focused Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best way to collect tissue samples from lung cancer patients using a thin tube passed through the mouth (endobronchial ultrasound). It compares taking 2 versus 3 samples from each lymph node to see if fewer samples still provide enough material for genetic testing. It also checks if a simple blood test (liquid biopsy) can find genetic changes that the tissue sample might miss. The goal is to make testing easier and more complete for people with suspected non-small cell lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endobronchial ultrasound (EBUS) procedure with 2 or 3 needle passes per lymph node, plus liquid biopsy (blood test)
What this could lead to
If successful, this could help doctors get enough tissue for genetic testing with fewer needle passes, and show that a blood test can find important genetic changes missed by tissue biopsy.
What could go wrong
This is a small, early-stage study (120 people) at one hospital, so results may not apply to everyone. It tests a procedure, not a new drug, so it won't directly treat lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suspected or confirmed NSCLC requiring tissue sample for NGS testing to guide clinical management * Presence of at least 2 targets accessible by EBUS or EUS suspicious of malignancy (primary tumor, lymph node \> 10mm or with Standardized Uptake Value (SUV) \> 2.5) Exclusion Criteria: * Other modality then EBUS judged preferable by treating physician to obtain tumoral tissue for NGS testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circulating tumor cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm Neoplastic Cells, Circulating non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Circulating tumor cell Lung cancer Non-small cell lung cancer

Contacts and locations

Locations

  • Institut Universitaire de Cardiologie et Pneumologie de Quebec

    Québec, Quebec, G1V4G5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.